- Home
- SOAR vs BLRX Comparison
SOAR vs BLRX Comparison
Compare SOAR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- BLRX
- Stock Information
- Founded
- SOAR 2021
- BLRX 2003
- Country
- SOAR United States
- BLRX Israel
- Employees
- SOAR N/A
- BLRX N/A
- Industry
- SOAR Blank Checks
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- BLRX Health Care
- Exchange
- SOAR Nasdaq
- BLRX Nasdaq
- Market Cap
- SOAR 15.7M
- BLRX 17.1M
- IPO Year
- SOAR N/A
- BLRX 2011
- Fundamental
- Price
- SOAR $1.40
- BLRX $3.45
- Analyst Decision
- SOAR
- BLRX Strong Buy
- Analyst Count
- SOAR 0
- BLRX 2
- Target Price
- SOAR N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SOAR 1.4M
- BLRX 23.6K
- Earning Date
- SOAR 11-18-2025
- BLRX 11-20-2025
- Dividend Yield
- SOAR N/A
- BLRX N/A
- EPS Growth
- SOAR N/A
- BLRX N/A
- EPS
- SOAR N/A
- BLRX N/A
- Revenue
- SOAR $96,397,000.00
- BLRX $17,251,000.00
- Revenue This Year
- SOAR N/A
- BLRX N/A
- Revenue Next Year
- SOAR N/A
- BLRX N/A
- P/E Ratio
- SOAR N/A
- BLRX N/A
- Revenue Growth
- SOAR 309.80
- BLRX 1.19
- 52 Week Low
- SOAR $1.14
- BLRX $2.30
- 52 Week High
- SOAR $19.06
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- SOAR 38.78
- BLRX 42.01
- Support Level
- SOAR $1.25
- BLRX $3.10
- Resistance Level
- SOAR $1.73
- BLRX $3.52
- Average True Range (ATR)
- SOAR 0.19
- BLRX 0.21
- MACD
- SOAR -0.07
- BLRX -0.01
- Stochastic Oscillator
- SOAR 14.57
- BLRX 37.97
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.